Teva Pharmaceutical Industries Ltd.'s bid to dismiss antitrust claims should be denied in a case where Mylan Pharmaceuticals Inc. alleges the company unlawfully delayed a generic version of a multiple ...
The S&P 500 (SP500) hit new highs during February trade, but that wasn’t enough to stave off a monthly loss. The benchmark ...
In high-income countries, more than 80% of children diagnosed with cancer will survive. Yet in some low- and middle-income ...
Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and ...
In a report released yesterday, Jason Gerberry from Bank of America Securities reiterated a Buy rating on Arcellx Inc (ACLX – Research Report).
Israeli drug manufacturer Teva Pharmaceutical Industries has resumed the deliveries of the scarce epilepsy drug Finlepsin ...
The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.
23h
Hosted on MSNMandatory drug stock monitoring empowers EU to tackle shortagesThe MSSG solidarity mechanism enables medicine sharing between EU states, with companies now required to report on drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results